Fundraising FoxVergent Bioscience
Minneapolis, US · 3 known investors
Find your way into Vergent Bioscience
Sign up to see every warm intro you have to Vergent Bioscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vergent Bioscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vergent develops tumor-targeted fluorescent imaging agents designed to enhance surgeons' ability to visualize tumors during minimally invasive and robotic-assisted cancer surgery. The company's lead program, abenacianine for injection, is in Phase 2b clinical evaluation for lung cancer surgery applications.
Founders & leadership
Board
Investors · 3
How we know: Colle Capital Partners's portfolio page · Not right? Tell us
How we know: Windham Capital Partners's portfolio page · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$57M disclosed across 5 of 6 rounds · 2018–2025
▶$18.7MraisedOct 2025 · 20 investors · BiotechnologyRule 506(b)
- Bobby HelmedagDirector
- Jeffrey YureckoExecutive Officer
- Anita WatkinsDirector
- John T. Santini, Jr.Executive Officer, Director
- Raymond WongDirector
- Douglas KohrsDirector
- Offering amount
- $32M
- Amount sold
- $18.7M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedFeb 2025 · 5 investors · BiotechnologyRule 506(b)
- Jeff JulkowskiDirector
- Douglas KohrsDirector
- Raymond WongDirector
- Jeffrey YureckoExecutive Officer
- John SantiniExecutive Officer, Director
- Anita WatkinsDirector
- Samuel Dean BanksDirector
- Ryan EgelandDirector
- Bobby HelmedagDirector
- Offering amount
- $5M
- Amount sold
- $3.8M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21.5MraisedOct 2022 · 27 investors · BiotechnologyRule 506(b)
- Ryan EgelandDirector
- John SantiniExecutive Officer, Director
- Margo ShoupDirector
- Douglas KohrsDirector
- Jeffrey YureckoExecutive Officer
- Raymond WongDirector
- Jeffrey JulkowskiDirector, Promoter
- Samuel BanksDirector
- Offering amount
- $22.1M
- Amount sold
- $21.5M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedNov 2021 · 16 investors · BiotechnologyRule 506(b)
- Jeffrey JulkowskiDirector, Promoter
- Raymond WongDirector
- John SantiniExecutive Officer, Director
- Ryan EgelandDirector
- Samuel Dean BanksDirector
- Douglas KohrsDirector
- Jeffrey YureckoExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1.2M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.9MraisedSep 2020 · 21 investors · BiotechnologyRule 506(b)
- Samuel Dean BanksDirector
- Douglas KohrsDirector
- Ryan EgelandDirector
- John SantiniExecutive Officer, Director
- Jeffrey JulkowskiDirector, Promoter
- Jeffrey YureckoExecutive Officer
- Raymond WongDirector
- Offering amount
- $11.9M
- Amount sold
- $11.9M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Vergent Bioscience do?
- Vergent develops tumor-targeted fluorescent imaging agents designed to enhance surgeons' ability to visualize tumors during minimally invasive and robotic-assisted cancer surgery. The company's lead program, abenacianine for injection, is in Phase 2b clinical evaluation for lung cancer surgery applications.
- Who are Vergent Bioscience's investors?
- Vergent Bioscience's investors include Colle Capital Partners, Windham Capital Partners, Spring Mountain Capital.
- How much funding has Vergent Bioscience raised?
- Vergent Bioscience has disclosed $57M raised across 5 of its 6 known rounds.
- Where is Vergent Bioscience headquartered?
- Vergent Bioscience is headquartered in Minneapolis, US.